Complications and risks in hematopoietic stem cell transplant patients.

L. A. Smith, M. S. Wright-Kanuth

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    Hematopoietic stem cell transplantation is a recognized treatment for hematological diseases such as leukemia and lymphoma, certain solid organ tumors, and a limited number of immunologic disorders. The major risks associated with this procedure are infections and development of graft-vs-host disease. Bacterial or viral agents are the most common cause of infections, but fungal and protozoan organisms may also be isolated. Bacterial infections occur most frequently in the first 30 days after transplant, whereas the onset of viral infections usually occurs later during the first three months posttransplant. Studies have demonstrated that there are a variety of predisposing factors that influence the type of infection a patient develops. These include underlying disease, type of chemotherapy regimen, type of antimicrobial and antiviral regimen, presence of graft-vs-host disease, and period of severe neutropenia posttransplant. Of these, the period of neutropenia appears to be the most significant. Graft-vs-host disease is seen in those patients who have received allogeneic hematopoietic stem cell transplants. New antimicrobial and antiviral agents and manipulation of the hematopoietic stem cell transplant to select specific cell types for infusion have provided some methods to prevent or decrease the number and severity of infections or to prevent/control graft-vs-host disease.

    Original languageEnglish (US)
    Pages (from-to)118-124
    Number of pages7
    JournalClinical laboratory science : journal of the American Society for Medical Technology
    Volume14
    Issue number2
    StatePublished - Mar 2001

    Fingerprint

    Transplants
    Graft vs Host Disease
    Hematopoietic Stem Cells
    Stem cells
    Grafts
    Neutropenia
    Antiviral Agents
    Infection
    Protozoan Infections
    Mycoses
    Hematologic Diseases
    Hematopoietic Stem Cell Transplantation
    Virus Diseases
    Anti-Infective Agents
    Bacterial Infections
    Causality
    Transplantation (surgical)
    Lymphoma
    Leukemia
    Chemotherapy

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)

    Cite this

    Complications and risks in hematopoietic stem cell transplant patients. / Smith, L. A.; Wright-Kanuth, M. S.

    In: Clinical laboratory science : journal of the American Society for Medical Technology, Vol. 14, No. 2, 03.2001, p. 118-124.

    Research output: Contribution to journalArticle

    @article{4f8dbf632e784bd2b5d4d90f5e769050,
    title = "Complications and risks in hematopoietic stem cell transplant patients.",
    abstract = "Hematopoietic stem cell transplantation is a recognized treatment for hematological diseases such as leukemia and lymphoma, certain solid organ tumors, and a limited number of immunologic disorders. The major risks associated with this procedure are infections and development of graft-vs-host disease. Bacterial or viral agents are the most common cause of infections, but fungal and protozoan organisms may also be isolated. Bacterial infections occur most frequently in the first 30 days after transplant, whereas the onset of viral infections usually occurs later during the first three months posttransplant. Studies have demonstrated that there are a variety of predisposing factors that influence the type of infection a patient develops. These include underlying disease, type of chemotherapy regimen, type of antimicrobial and antiviral regimen, presence of graft-vs-host disease, and period of severe neutropenia posttransplant. Of these, the period of neutropenia appears to be the most significant. Graft-vs-host disease is seen in those patients who have received allogeneic hematopoietic stem cell transplants. New antimicrobial and antiviral agents and manipulation of the hematopoietic stem cell transplant to select specific cell types for infusion have provided some methods to prevent or decrease the number and severity of infections or to prevent/control graft-vs-host disease.",
    author = "Smith, {L. A.} and Wright-Kanuth, {M. S.}",
    year = "2001",
    month = "3",
    language = "English (US)",
    volume = "14",
    pages = "118--124",
    journal = "Journal of Medical Technology",
    issn = "0894-959X",
    publisher = "American Society for Clinical Laboratory Science",
    number = "2",

    }

    TY - JOUR

    T1 - Complications and risks in hematopoietic stem cell transplant patients.

    AU - Smith, L. A.

    AU - Wright-Kanuth, M. S.

    PY - 2001/3

    Y1 - 2001/3

    N2 - Hematopoietic stem cell transplantation is a recognized treatment for hematological diseases such as leukemia and lymphoma, certain solid organ tumors, and a limited number of immunologic disorders. The major risks associated with this procedure are infections and development of graft-vs-host disease. Bacterial or viral agents are the most common cause of infections, but fungal and protozoan organisms may also be isolated. Bacterial infections occur most frequently in the first 30 days after transplant, whereas the onset of viral infections usually occurs later during the first three months posttransplant. Studies have demonstrated that there are a variety of predisposing factors that influence the type of infection a patient develops. These include underlying disease, type of chemotherapy regimen, type of antimicrobial and antiviral regimen, presence of graft-vs-host disease, and period of severe neutropenia posttransplant. Of these, the period of neutropenia appears to be the most significant. Graft-vs-host disease is seen in those patients who have received allogeneic hematopoietic stem cell transplants. New antimicrobial and antiviral agents and manipulation of the hematopoietic stem cell transplant to select specific cell types for infusion have provided some methods to prevent or decrease the number and severity of infections or to prevent/control graft-vs-host disease.

    AB - Hematopoietic stem cell transplantation is a recognized treatment for hematological diseases such as leukemia and lymphoma, certain solid organ tumors, and a limited number of immunologic disorders. The major risks associated with this procedure are infections and development of graft-vs-host disease. Bacterial or viral agents are the most common cause of infections, but fungal and protozoan organisms may also be isolated. Bacterial infections occur most frequently in the first 30 days after transplant, whereas the onset of viral infections usually occurs later during the first three months posttransplant. Studies have demonstrated that there are a variety of predisposing factors that influence the type of infection a patient develops. These include underlying disease, type of chemotherapy regimen, type of antimicrobial and antiviral regimen, presence of graft-vs-host disease, and period of severe neutropenia posttransplant. Of these, the period of neutropenia appears to be the most significant. Graft-vs-host disease is seen in those patients who have received allogeneic hematopoietic stem cell transplants. New antimicrobial and antiviral agents and manipulation of the hematopoietic stem cell transplant to select specific cell types for infusion have provided some methods to prevent or decrease the number and severity of infections or to prevent/control graft-vs-host disease.

    UR - http://www.scopus.com/inward/record.url?scp=16644365126&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=16644365126&partnerID=8YFLogxK

    M3 - Article

    C2 - 15625985

    AN - SCOPUS:16644365126

    VL - 14

    SP - 118

    EP - 124

    JO - Journal of Medical Technology

    JF - Journal of Medical Technology

    SN - 0894-959X

    IS - 2

    ER -